Novartis, FTC agreement paves way for $16bn buyout of GSK’s cancer unit

24-02-2015

Novartis, FTC agreement paves way for $16bn buyout of GSK’s cancer unit

© GSK

Swiss pharmaceutical company Novartis can buy London-based GlaxoSmithKline’s (GSK) portfolio of cancer drugs after it agreed to meet certain conditions set by the US Federal Trade Commission (FTC), the agency has said.


FTC, Novartis, GSK, M&A, cancer, BRAF, MEK

LSIPR